ATAI Life SciencesATAI
ATAI
About: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Employees: 54
0
Funds holding %
of 7,321 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
228% more call options, than puts
Call options by funds: $1.27M | Put options by funds: $388K
54% more capital invested
Capital invested by funds: $19.3M [Q4 2024] → $29.7M (+$10.4M) [Q1 2025]
2.39% more ownership
Funds ownership: 8.66% [Q4 2024] → 11.05% (+2.39%) [Q1 2025]
10% less funds holding
Funds holding: 88 [Q4 2024] → 79 (-9) [Q1 2025]
19% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 21
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
210%
upside
Avg. target
$11
241%
upside
High target
$12
272%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Sumant Kulkarni | 272%upside $12 | Buy Maintained | 2 Jul 2025 |
HC Wainwright & Co. Patrick Trucchio | 210%upside $10 | Buy Reiterated | 20 May 2025 |
Financial journalist opinion
Based on 10 articles about ATAI published over the past 30 days
Positive
Proactive Investors
1 day ago
Spravato sales momentum underscores market potential for psychedelics, atai Life Sciences seen as key beneficiary
Sales of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato grew sequentially in the second quarter, marking a positive sign for the broader psychedelics sector, according to Jefferies analysts. Spravato sales grew 29% quarter-over-quarter to $414 million worldwide.
Positive
Zacks Investment Research
1 week ago
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
Positive
Proactive Investors
2 weeks ago
atai Life Sciences price target boosted on robust BPL-003 mid-stage trial results
The atai Life Sciences (NASDAQ:ATAI, ETR:9VC) story has become more attractive following the release of robust Phase 2b trial results for BPL-003 in treatment-resistant depression, analysts at Jefferies believe. BPL-003, an intranasal formulation of DMT developed in partnership in Beckley Psytech, demonstrated rapid, robust and durable antidepressant effects with a single dose.
Positive
Seeking Alpha
2 weeks ago
Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD
Atai Life Sciences' BPL-003 showed robust, rapid, and durable antidepressant effects in Phase 2b TRD data, spiking shares over 20%. BPL-003's short clinic time and strong efficacy could fit existing treatment paradigms, potentially rivaling J&J's Spravato if regulatory hurdles are cleared. Regulatory approval remains uncertain due to controlled substance scheduling, but Atai's differentiated pipeline and patent position offer significant long-term upside.
Positive
Proactive Investors
2 weeks ago
Atai and Beckley Psytech hail DMT trial results in treatment-resistant depression
Atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced positive topline results from its Phase 2b clinical study in patients with treatment-resistant depression, and a private placement for gross proceeds of $50 million. The clincial study, in partnership with Beckley Psytech, is evaluating BPL-003, a formulation of the psychedelic compound mebufotenin, also known as DMT, that is administered using a nasal spray.
Positive
Benzinga
2 weeks ago
Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data
Atai Life Sciences ATAI and Beckley Psytech Limited jointly announced topline results from the eight-week, quadruple-masked, dose-finding core stage of the Phase 2b trial of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with treatment-resistant depression (TRD).
Neutral
GlobeNewsWire
2 weeks ago
atai Life Sciences Announces $50 Million Private Placement Financing
Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1 Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1
Neutral
GlobeNewsWire
2 weeks ago
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biopharmaceutical company pioneering the next generation of mental health treatments, today jointly announced positive topline results from the eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial evaluating the efficacy and safety of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with treatment-resistant depression (TRD). The study achieved its primary endpoint as well as all key secondary endpoints. At Day 29, a single 12 mg dose of BPL-003 demonstrated a statistically significant reduction in depressive symptoms, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with a mean decrease of 11.1 points from baseline compared to a 5.8 point reduction in the 0.3 mg comparator group (p = 0.0038). For the key secondary efficacy endpoints, a single 8 mg dose of BPL-003 also showed significant improvement at Day 29, with a mean MADRS score reduction of 12.1 points (p=0.0025 for change vs. 0.3 mg control). Notably, both the 8mg and 12mg doses of BPL-003 showed statistically significant improvements in MADRS scores as early as one day after dosing, with effects generally maintained out to Week 8.
Negative
Zacks Investment Research
3 weeks ago
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?
Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
Positive
Proactive Investors
3 weeks ago
atai Life Sciences backed by positive sector readthrough from Compass Phase 3 data, analysts say
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) remains a ‘Buy' for analysts at Jefferies, who continue to see significant upside ahead for the company following the release of new data from Compass Pathways (NASDAQ:CMPS)' late-stage trial of its synthetic psilocybin COMP360 in treatment-resistant depression (TRD). Compass Pathways on Monday reported that its COMP360 therapy reached its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in depression symptom severity compared to placebo.
Charts implemented using Lightweight Charts™